Skip to main content
. 2020 Nov;12(11):7011–7023. doi: 10.21037/jtd-2019-cptn-07

Table 2. Selected current clinical trials of immunotherapy for locally advanced lung cancer.

Study Drug Trial Phase Treatment Arm(s) Enrollment (actual or planned) Primary Endpoint
NCT02434081 (NICOLAS) Nivolumab 2 CRT +/– concurrent Nivolumab 94 Grade 3+ pneumonitis
NCT03519971 Durvalumab 3 CRT +/– concurrent Durvalumab 328 PFS and ORR

CRT, chemoradiation therapy; PFS, progression-free survival; ORR, objective response rate.